Carcinoma, Non-Small-Cell Lung Clinical Trial
Official title:
Phase I Study of Sequential Depsipeptide/Flavopiridol Infusion for Malignancies Involving Lungs, Esophagus, Pleura, Thymus or Mediastinum
This study will test the safety and effectiveness of two experimental medicines -
depsipeptide and flavopiridol - given together to treat cancers of the lung, esophagus, and
pleura. It will determine the highest dose that these drugs can safely be given together and
will test whether giving them together works better at shrinking tumors than giving either
one alone.
Patients 18 years of age and older with cancer of the lung, esophagus, or pleura, or other
cancers that have spread to the lungs or pleura may be eligible for this study. Candidates
are screened with a medical history and physical examination, blood tests, electrocardiogram
(EKG), x-rays and scans, pulmonary function tests, and a tumor biopsy (removal of a small
piece of tumor tissue for microscopic examination).
Participants are admitted to the hospital for treatment for approximately 10 days during each
28-day treatment cycle. Depsipeptide is infused through an arm vein or central venous
catheter (tube placed in a large vein in the neck or chest) for 4 hours. When this infusion
is complete, flavopiridol is infused over 72 hours. The dose of depsipeptide is increased
four times over the period of the study with successive groups of patients, and flavopiridol
is increased once to determine the maximum safe dose of giving these drugs together.
Blood tests are done before and after each depsipeptide infusion and 3 more times for the
next 24 hours, and at various times over 4 days during the flavopiridol infusion to evaluate
the effects of the medicines. Samples are also drawn periodically throughout the treatment
cycle to evaluate safety. Heart function is monitored with several EKGs before and during the
depsipeptide doses. The drug has shown effects on EKG tracings, but does not appear to injure
the heart muscle.
Tumor biopsies are done before treatment begins and on the fifth day of the first treatment
cycle. The biopsies may be done either in the operating room by passing a tube (bronchoscope)
down the throat and into the lungs or in the Radiology Department using a thin needle put
through the chest wall into the tumor. For the bronchoscopy, numbing medicine is sprayed into
the back of the throat to reduce discomfort, and for the needle biopsy, the skin over the
biopsy area is numbed. Optional repeat biopsies may be requested before the start of the
second treatment cycle and on day 5 of that cycle. (The repeat biopsies are not required for
participation in the study.) At the time of each tumor biopsy, a buccal mucosal biopsy is
also done. This involves scraping a tongue depressor along the inside of the mouth to collect
cells for examination.
At the end of the first treatment cycle, patients return to NIH for evaluation with a
physical examination, blood work, x-rays, and scans of the chest, abdomen, pelvis, and brain.
Patients who are not experiencing significant drug side effects are offered a second cycle,
exactly like the first. The two cycles complete one course of treatment, after which patients
once again return to NIH for evaluation. Additional treatment cycles may be offered to
patients whose tumors have shrunk or remained stable with therapy. Patients whose tumors have
not responded to therapy or who have developed severe drug side effects are taken off the
study.
Background:
In preclinical studies we have demonstrated that the histone deacetylase (HDAC) inhibitor
Depsipeptide FR901228 (DP) mediates cell cycle arrest and apoptosis in cultured lung and
esophageal cancer, and malignant pleural mesothelioma cells.
We have observed that the cdk inhibitor Flavopiridol (FLA) markedly potentiates
Depsipeptide-mediated apoptosis in cultured cancer cells, but not cultured normal epithelial
cells.
Patients with advanced malignancies involving lungs, esophagus, or pleura will receive 4-hour
Depsipeptide infusion followed by 72-hour FLA infusion using a phase I study design.
Tumor and buccal mucosa biopsies as well as PBMC may be obtained prior to, and after therapy
to evaluate gene expression using cDNA array long-oligo and protein lysate array techniques,
and determine if sequential DP/FLA mediates apoptosis in target tissues.
Results of these studies may provide the rationale for phase II evaluation of sequential
DP/FLA infusion in thoracic oncology patients.
Objectives:<TAB>
Primary objectives:
To define the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of sequential 4
hour Depsipeptide(DP)/72 hour Flavopiridol (FLA)
To evaluate the pharmacokinetics of sequential DP/FLA infusion
Secondary objectives
To analyze gene expression profiles in laser-captured tumor cells, buccal mucosa, and PBMC
before and after sequential DP/FLA exposure.
To analyze mcl-1 protein expression and apoptosis in tumor biopsies before and after
sequential DP/FLA treatment.
Tertiary objectives:
The development of tissue and serum proteomic techniques to assess treatment response in
patients receiving sequential DP/FLA infusions.
Eligibility:
Patients with histologically or cytologically proven primary small cell or non-small cell
lung cancers, esophageal cancers, malignant pleural mesotheliomas or chest wall sarcoma, or
thymomas are eligible for evaluation. In addition, patients with cancers of nonthoracic
origin with metastases to the lungs or pleura, or germ cell tumors refractory to standard
therapy are eligible for evaluation.
Patients must have an ECOG performance status of 0 - 2.
Patients must have adequate pulmonary reserve evidenced by FEV1 and DLCO greater than the 30
percent predicted, and pCO2 less than 50 mm Hg and pO2 greater than 60 mm Hg on room air ABG.
Patients must be 18 years of age or older.
Adequate organ function as evidenced by standard laboratory parameters.
The patient must be willing to sign an informed consent.
Design:<TAB><TAB>
A phase 1 study where patient cohorts will receive escalating doses of Depsipeptide,
administered on day 1 and day 21, and a dose of flavopiridol (either 40 mg/m2/d or 50
mg/m2/d) administered on days 1-3, and 21-24 of a 42-day course.
Pharmacokinetics, systemic toxicity, and response to therapy will be recorded.
Two cycles of therapy (one course) will be administered, following which treatment evaluation
will be performed using standard clinical criteria.
48 patients will be enrolled over a period of 2-4 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |